RecruitingPhase 2NCT04690348

Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study


Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

103 participants

Start Date

Dec 24, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to see if Cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). The researchers would like to see whether Cs-131 prevents brain tumors from growing back after surgery.The researchers will compare Cs-131 brachytherapy (which occurs during brain surgery) with the usual approach of brain surgery without brachytherapy. The researchers will compare both the effectiveness and safety of the two approaches.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Adult patients ≥ 18 years of age who are capable of giving consent
  • Undergoing elective craniotomy for resection of a previously-irradiated brain metastasis with suspicion for viable disease at the time of consent, and anticipated achievement of gross-total or near-total (\>/=95%) resection
  • Karnofsky Performance Status score (KPS) of ≥70
  • Ability to undergo brain MRI with gadolinium

Exclusion Criteria10

  • Unable to tolerate MRI or CT imaging
  • Pregnancy (patients must have a negative pregnancy test within 30 days of the operation)
  • Women must agree to not breastfeed for at least 12 weeks after the procedure (lactating and discarding in that interval allowable)
  • Diagnosis of leptomeningeal carcinomatosis or \>5 additional active or untreated CNS lesions for a total of \>6 active lesions
  • Prior irradiation (EQD2) in excess of 100 Gy to site of implant, using an α/β of 2
  • Apposition of tumor margin to brainstem or optic apparatus
  • Previous infection within the operative field, current active systemic infection requiring systemic therapy, or immunodeficiency
  • Urgent surgery required prior to availability of brachytherapy
  • Intraoperative Exclusion Criterion:
  • Patients will be excluded if intraoperative pathology is not consistent with \>/=5% viable metastatic disease.

Interventions

PROCEDURECraniotomy

Craniotomy

RADIATIONCesium-131 brachytherapy

Intracavitary Cesium-131 brachytherapy


Locations(6)

Baptist Health South Florida

Miami, Florida, United States

Memorial Sloan Kettering at Basking Ridge (Consent Only)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Consent Only)

Middletown, New Jersey, United States

Memorial Sloan Kettering Commack (Consent Only)

Commack, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04690348


Related Trials